Cannara Biotech is a purchase, Analysis Capital says

Analysis Capital analyst Greg McLeish mentioned in a July 29 replace that Cannara Biotech (Cannara Biotech Inventory Quote, Chart, Information, Analysts, Financials TSXV:LOVE) delivered a robust fiscal third quarter, beating expectations on income and working efficiency. The corporate reported $27.3-million in income for the interval ended Could 31, 2025, forward of McLeish’s $26.3-million forecast and up from $19.5-million a 12 months earlier, pushed by new product launches and broader market penetration.

McLeish maintained his “Purchase” ranking and $3.00 goal value for the inventory.

“Gross margin of 44% was effectively forward of our 40% estimate, reflecting elevated manufacturing capability and operational efficiencies,” he mentioned. Adjusted EBITDA rose to $7.6-million, exceeding the $5.2-million forecast and greater than doubling year-over-year. Web revenue got here in at $4.1-million, or $0.04 per share, additionally beating expectations.

“Cannara is scaling its manufacturing platform by way of a disciplined, modular growth technique that greater than doubles present capability for a complete capital funding of simply $22-million,” McLeish mentioned. “Via intensive R&D and optimization of cultivation practices, the corporate has achieved a 26% improve in yield, elevating its annual manufacturing capability from 39,500 kg to 50,000 kg, reaching its unique F2026 goal a full 12 months forward of schedule and with out incremental capital outlay. Wanting ahead, Cannara has revised its manufacturing targets upward: to 65,000 kg in F2027 (from 62,500 kg) and to 80,000 kg in F2028 (from 75,000 kg). At full build-out, the Valleyfield facility is designed to assist as much as 100,000 kg of annual output, providing substantial latent capability and long-term working leverage as demand continues to scale.”

Cannara plans to finish a $10-million processing centre at its Valleyfield facility throughout fiscal 2026. The brand new centre will present the drying and trimming capability wanted to assist growth throughout develop rooms 13 to 24.

McLeish mentioned the anticipated legalization of hashish vape cartridges in Quebec by late 2025 may very well be a serious structural development catalyst for Cannara. Although at present banned, about 25% of Quebec shoppers already use vapes by way of illicit channels, revealing robust underlying demand.

“On July 24, Cannara introduced the preliminary approval of 5 vape SKUs, comprising each stay resin and solventless stay rosin codecs, for province-wide distribution,” he mentioned. “These merchandise signify 20% of the 25 vape SKUs the SQDC intends to launch throughout its 107 shops by calendar year-end. Given Cannara’s ~12% retail market share in Quebec and its place as Canada’s main supplier of stay resin vapes, the corporate is exceptionally well-positioned to capitalize on this new class in its core provincial market.”

McLeish thinks that Cannara will do $25.1-million in Adjusted EBITDA on income of $104.0-million in fiscal 2025. He thinks these numbers will enhance to $33.7-million on income of $121.2-million in fiscal 2026.

He mentioned the ranking and goal are unchanged, backed by Cannara’s cost-efficient Quebec base, vertical integration, and robust premium product execution. Q3 outcomes mirror strong value self-discipline and development in classes like vapes and concentrates. The goal relies on 8.0x FY2027 EBITDA.

-30-